Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluorine-18-THK 5351

Next Previous
Drug Profile

Fluorine-18-THK 5351

Alternative Names: 3H-THK5351; [18F]THK-5351; F-18 THK-5351; FluoroTau; GE-216

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tohoku University
  • Developer Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; GE Healthcare; Tohoku University
  • Class Antidementias; Imaging agents; Pyridines; Quinolines; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Neurodegenerative disorders
  • No development reported Aphasia; Lewy body disease; Mild cognitive impairment; Progressive supranuclear palsy

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for clinical-Phase-Unknown development in Alzheimer's-disease(Diagnosis) in Japan (IV, Injection)
  • 28 Nov 2019 No recent reports of development identified for clinical-Phase-Unknown development in Lewy body disease(Diagnosis) in Japan (IV, Injection)
  • 28 Nov 2019 No recent reports of development identified for clinical-Phase-Unknown development in Mild-cognitive-impairment(Diagnosis) in Japan (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top